Literature DB >> 22954387

Small molecule inhibitors of Bacillus anthracis protective antigen proteolytic activation and oligomerization.

Alexander N Wein1, Brian N Williams, Shihui Liu, Boris Ermolinsky, Daniele Provenzano, Ruben Abagyan, Andrew Orry, Stephen H Leppla, Michael Peredelchuk.   

Abstract

Protective antigen (PA), lethal factor, and edema factor, the protein toxins of Bacillus anthracis , are among its most important virulence factors and play a key role in infection. We performed a virtual ligand screen of a library of 10000 members to identify compounds predicted to bind to PA and prevent its oligomerization. Four of these compounds slowed PA association in a FRET-based oligomerization assay, and two of those protected cells from intoxication at concentrations of 1-10 μM. Exploration of the protective mechanism by Western blot showed decreased SDS-resistant PA oligomer on cells and, surprisingly, decreased amounts of activated PA. In vitro assays showed that one of the inhibitors blocked furin-mediated cleavage of PA, apparently through its binding to the PA substrate. Thus, we have identified inhibitors that can independently block both PA's cleavage by furin and its subsequent oligomerization. Lead optimization on these two backbones may yield compounds with high activity and specificity for the anthrax toxins.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22954387      PMCID: PMC3474531          DOI: 10.1021/jm300804e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  65 in total

1.  Lethal factor of Bacillus anthracis cleaves the N-terminus of MAPKKs: analysis of the intracellular consequences in macrophages.

Authors:  R Pellizzari; C Guidi-Rontani; G Vitale; M Mock; C Montecucco
Journal:  Int J Med Microbiol       Date:  2000-10       Impact factor: 3.473

2.  Designing a polyvalent inhibitor of anthrax toxin.

Authors:  M Mourez; R S Kane; J Mogridge; S Metallo; P Deschatelets; B R Sellman; G M Whitesides; R J Collier
Journal:  Nat Biotechnol       Date:  2001-10       Impact factor: 54.908

3.  Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.

Authors:  S Liu; T H Bugge; S H Leppla
Journal:  J Biol Chem       Date:  2001-03-12       Impact factor: 5.157

4.  Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo.

Authors:  Miroslav S Sarac; Juan R Peinado; Stephen H Leppla; Iris Lindberg
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

5.  Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation.

Authors:  D Borden Lacy; Darran J Wigelsworth; Roman A Melnyk; Stephen C Harrison; R John Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

6.  Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin.

Authors:  S Liu; S Netzel-Arnett; H Birkedal-Hansen; S H Leppla
Journal:  Cancer Res       Date:  2000-11-01       Impact factor: 12.701

7.  Crystal structure of a complex between anthrax toxin and its host cell receptor.

Authors:  Eugenio Santelli; Laurie A Bankston; Stephen H Leppla; Robert C Liddington
Journal:  Nature       Date:  2004-07-04       Impact factor: 49.962

8.  Cross-inhibition between furin and lethal factor inhibitors.

Authors:  Juan R Peinado; Magdalena M Kacprzak; Stephen H Leppla; Iris Lindberg
Journal:  Biochem Biophys Res Commun       Date:  2004-08-27       Impact factor: 3.575

9.  Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells.

Authors:  S H Leppla
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

10.  Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome.

Authors:  Jonathan L Levinsohn; Zachary L Newman; Kristina A Hellmich; Rasem Fattah; Matthew A Getz; Shihui Liu; Inka Sastalla; Stephen H Leppla; Mahtab Moayeri
Journal:  PLoS Pathog       Date:  2012-03-29       Impact factor: 6.823

View more
  4 in total

Review 1.  Designing inhibitors of anthrax toxin.

Authors:  Ekaterina M Nestorovich; Sergey M Bezrukov
Journal:  Expert Opin Drug Discov       Date:  2014-01-22       Impact factor: 6.098

Review 2.  An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

Authors:  Lernik Ohanjanian; Kenneth E Remy; Yan Li; Xizhong Cui; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2015-04-28       Impact factor: 6.206

3.  Monitoring the kinetics of the pH-driven transition of the anthrax toxin prepore to the pore by biolayer interferometry and surface plasmon resonance.

Authors:  Subhashchandra Naik; Susan Brock; Narahari Akkaladevi; Jon Tally; Wesley McGinn-Straub; Na Zhang; Phillip Gao; E P Gogol; B L Pentelute; R John Collier; Mark T Fisher
Journal:  Biochemistry       Date:  2013-09-09       Impact factor: 3.162

4.  Targeting Bacillus anthracis toxicity with a genetically selected inhibitor of the PA/CMG2 protein-protein interaction.

Authors:  Abigail L Male; Fedor Forafonov; Francesco Cuda; Gong Zhang; Siqi Zheng; Petra C F Oyston; Peng R Chen; E Diane Williamson; Ali Tavassoli
Journal:  Sci Rep       Date:  2017-06-08       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.